<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206452</url>
  </required_header>
  <id_info>
    <org_study_id>12153</org_study_id>
    <nct_id>NCT01206452</nct_id>
  </id_info>
  <brief_title>Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes</brief_title>
  <official_title>Use of Oral Steroids Before Circumferential Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation to Improve Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dhanunjaya Lakkireddy, MD, FACC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the efficacy of oral prednisone in improving
      the outcomes of pulmonary vein isolation with radiofrequency ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is:

        1. To assess the efficacy of oral prednisone in improving the outcomes of pulmonary vein
           isolation with radiofrequency ablation.

        2. To measure the inflammatory cytokine (TNF-α, IL-1, IL-6, IL-8) response to
           radiofrequency ablation for atrial fibrillation with or without prior prednisone
           treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. To assess the efficacy of oral prednisone in improving the outcomes of pulmonary vein isolation with radiofrequency ablation</measure>
    <time_frame>day of ablation, 1day and 2 days before the procedure.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokine (TNF-α, IL-1, IL-6, IL-8) response to radiofrequency ablation for atrial fibrillation with or without prior prednisone treatment.</measure>
    <time_frame>day of ablation, 1day and 2 days before the procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Ablation plus prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ablation plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ablation plus prednisone</intervention_name>
    <description>Ablation procedure plus 60mg of oral prednisone 2 days before procedure, 1 day before procedure, and day of procedure</description>
    <arm_group_label>Ablation plus prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ablation plus placebo</intervention_name>
    <description>Ablation procedure plus placebo 2 days before procedure, 1 day before procedure, and day of procedure</description>
    <arm_group_label>Ablation plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide written informed consent;

          2. Scheduled for radiofrequency ablation procedure for treatment of atrial fibrillation

        Exclusion Criteria:

          1. History of heart failure (right or left or biventricular) or cardiomyopathy.

          2. Immunosuppressive disorders and systemic fungal infection

          3. Concurrent use of corticosteroids in one week prior recruitment.

          4. Allergy or prednisone or its components.

          5. Other medical conditions were use of corticosteroids is not recommended or
             contraindicated.

          6. Patients with chronic and permanent atrial fibrillation.

          7. Patients with established diagnosis of rheumatological and immunological disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhanunjaya Lakkireddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>September 20, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Dhanunjaya Lakkireddy, MD, FACC</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation; Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
